Improvement of the Coxsackievirus B3 (CVB3)-induced mice-myocarditis model by development of a pancreas-attenuated virus

被引：0
作者：
Pryshliak, M. [1 ]
Pinkert, S. [1 ]
Hazini, A. [1 ]
Fechner, H. [1 ]
机构：
[1] Tech Univ Berlin, Berlin, Germany
来源：
HUMAN GENE THERAPY | 2016年 / 27卷 / 11期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
P423
引用
收藏
页码：A174 / A174
页数：1
相关论文
共 50 条
  • [21] An avirulent coxsackievirus B3 (CVB3/0) becomes virulent and pathogenic after passage through an aged host
    Gay, R
    Bronson, R
    Smith, DE
    Chung, HY
    Wu, DY
    Beck, MA
    Meydani, SN
    FASEB JOURNAL, 2003, 17 (04) : A665 - A665
  • [22] Protective effects of losartan in mice with chronic viral myocarditis induced by coxsackievirus B3
    Zhang, Yuan-Yuan
    Li, Jin-Nan
    Xia, Harry Hua-Xiang
    Zhang, Shi-Lun
    Zhong, Jiang
    Wu, Yi-Ying
    Miao, Shi-Kun
    Zhou, Li-Ming
    LIFE SCIENCES, 2013, 92 (24-26) : 1186 - 1194
  • [23] Development of troponin autoantibodies in experimental coxsackievirus B3 myocarditis
    Latva-Hirvela, J.
    Kyto, V.
    Saraste, A.
    Eriksson, S.
    Vuorinen, T.
    Pettersson, K.
    Saukko, P.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2009, 39 (06) : 457 - 462
  • [24] Inoculation of the attenuated Coxsackievirus B3 Sabin3-like strain induces a protection against virulent CVB3 Nancy and CVB4 E2 strains in Swiss mice by both oral and intraperitoneal routes
    Jrad-Battikh, Nadia
    Souii, Amira
    Hadhri, Rym
    Aouni, Mahjoub
    Gharbi, Jawhar
    Ben M'hadheb-Gharbi, Manel
    BIOLOGIA, 2014, 69 (01) : 113 - 121
  • [25] Inoculation of the attenuated Coxsackievirus B3 Sabin3-like strain induces a protection against virulent CVB3 Nancy and CVB4 E2 strains in Swiss mice by both oral and intraperitoneal routes
    Nadia Jrad-Battikh
    Amira Souii
    Rym Hadhri
    Mahjoub Aouni
    Jawhar Gharbi
    Manel Ben M’hadheb-Gharbi
    Biologia, 2014, 69 : 113 - 121
  • [26] VP1 sequence analysis and susceptibility of laboratory strains and clinical isolates of coxsackievirus B3 (CVB3) to pleconaril
    Schmidtke, M
    Hammerschmidt, E
    Zell, R
    Riabova, O
    Makarov, V
    Wutzler, P
    ANTIVIRAL RESEARCH, 2004, 62 (02) : A78 - A79
  • [27] Inhibition of Coxsackievirus B3 (CVB3) Replication by Self-Complementary AAV Vector-Based Expression of shRNAs Directed Against the RNA-Dependent RNA Polymerase of CVB3
    Sipo, Isaac
    Wang, Xiaomin
    Kurreck, Jens
    Weger, Stefan
    Zeichhardt, Heinz
    Poller, Wolfgang
    Fechner, Henry
    MOLECULAR THERAPY, 2006, 13 : S277 - S278
  • [28] QSAR studies demonstrate the influence of structure of [(biphenyloxy)propyl]isoxazole derivatives on inhibition of coxsackievirus B3 (CVB3) replication
    Muratov, E
    Artemenko, A
    Kuz'min, V
    Makarov, V
    Riabova, O
    Wutzler, P
    Schmidtke, M
    Lozitsky, V
    Fedchuk, A
    ANTIVIRAL RESEARCH, 2006, 70 (01) : A77 - A77
  • [29] Development of a new mouse model for coxsackievirus-inducedmyocarditis by attenuating coxsackievirus B3 virulence in the pancreas
    Pinkert, Sandra
    Pryshliak, Markian
    Pappritz, Kathleen
    Knoch, Klaus
    Hazini, Ahmet
    Dieringer, Babette
    Schaar, Katrin
    Dong, Fengquan
    Hinze, Luisa
    Lin, Jie
    Lassner, Dirk
    Klopfleisch, Robert
    Solimena, Michele
    Tschoepe, Carsten
    Kaya, Ziya
    El-Shafeey, Muhammad
    Beling, Antje
    Kurreck, Jens
    Van Linthout, Sophie
    Klingel, Karin
    Fechner, Henry
    CARDIOVASCULAR RESEARCH, 2020, 116 (10) : 1756 - 1766
  • [30] Effect of prophylactically applied CpG ODN on the development of myocarditis in mice infected with Coxsackievirus B3
    Zhao, Tiesuo
    Wu, Xiuli
    Song, Dandan
    Fang, Mingli
    Guo, Sheng
    Zhang, Peiyin
    Wang, Liying
    Wang, Liping
    Yu, Yongli
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2012, 14 (04) : 665 - 673
12345